Last reviewed · How we verify
NCT06313762
Use of Virtual Reality in the Reduction of Pain After the Administration of Vaccines Among Children in Primary Care Centers.
NA trial testing Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet in Pain in 300 participants. Completed in 8 February 2024.
24 January 2024
Quick facts
| Lead sponsor | Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 300 |
| Start date | 18 January 2022 |
| Primary completion | 24 January 2024 |
| Estimated completion | 8 February 2024 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Pico G2 Virtual Reality Glasses (Pico Interactive Inc), together with an Android AOYODKG tablet
- Traditional Distractors
- Triple Viral + Varicella Vaccine at 3 years of age — full drug profile →
- Hepatitis A + Diphtheria-Tetanus-Pertussis Vaccine at 6 years of age. — full drug profile →
Conditions studied
- Pain — all drugs for Pain →
- Pediatrics — all drugs for Pediatrics →
- Vaccination — all drugs for Vaccination →
- Virtual Reality — all drugs for Virtual Reality →
Sponsor
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina — full company profile →
Who can join
Adults 3 to 6, any sex, with Pain or Pediatrics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this randomized, multicenter, open-label, parallel, controlled clinical trial is to evaluate pain reduction during the administration of two vaccines in children aged 3 and 6 years through virtual reality. The main question\[s\] it aims to answer are: 1. To evaluate the reduction in pain during the administration of two vaccines in children aged 3 and 6 years. 2. To evaluate the reduction in anxiety during and after the administration of two vaccines in children aged 3 and 6 years. 3. Improve the satisfaction of parents or legal guardians after the administration of two vaccines in children aged 3 and 6 years. 4. Evaluate the Safety of the use of virtual reality glasses in children aged 3 and 6 years during the administration of vaccines. The study population will include children aged 3 and 6 years who are included in the patient registry and are being seen in a primary care center of the Catalan Institute of Health in Central Catalonia. The clinical trial has two assigned groups: a control group and an intervention group. The intervention group will use the Pico G2 VR goggles (Pico Interactive Inc) during the administration of the two vaccines, together with an Android AOYODKG tablet, which will be connected to the goggles as a controller. The control group participants will receive traditional distractors, such as being held by the parent or guardian who accompanies them to the appointment, receiving stickers at the end of the appointment, or receiving rewards that the parent or guardian has prepared from home. International Registered Report Identifier (IRRID): PRR1-10.2196/35910
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Use of virtual reality in the reduction of pain after the administration of vaccines among children in primary care centers in Central Catalonia: Randomized clinical trial.
De La Cruz Herrera M, Fuster-Casanovas A, Miró Catalina Q, Cigarrrán Mensa M, et al · · 2025 · PMID 40334011 · DOI 10.1371/journal.pone.0322840
Verify or expand the search:
- PubMed search for NCT06313762
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pain
Currently open trials in the same condition.
- NCT07533409 — Tactile and Pain Sensory Thresholds and Hand Grip Strength · recruiting
- NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
- NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting
Other Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina trials
Trials by the same sponsor.
- NCT07441759 — throMboembolic Risk Associated To High atrIal Fibrillation riSk · not yet recruiting
- NCT07132632 — Effect of a Multicomponent Therapeutic Exercise Program in Primary Care on Frailty and Sarcopenia in Older Adults · NA · not yet recruiting
- NCT07373119 — Improving Frailty in Patients With Stable Ischemic Heart Disease · NA · enrolling by invitation
- NCT06581367 — Tailoring Antibiotic Duration for Respiratory Tract Infections in Primary Care · Phase 4 · not yet recruiting
- NCT06988904 — ENERGY2MOB STUDY: OBESITY MANAGEMENT IN BERGUEDÀ · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06313762 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
- Last refreshed: 15 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06313762.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing